Constitutive BRCA1 promoter hypermethylation can be a predisposing event in isolated early-onset breast cancer

Jacopo Azzollini, Chiara Pesenti, Sara Pizzamiglio, Laura Fontana, Carmela Guarino, Bernard Peissel, Maddalena Plebani, Silvia Tabano, Silvia Maria Sirchia, Patrizia Colapietro, Roberta Villa, Biagio Paolini, Paolo Verderio, Monica Miozzo, Siranoush Manoukian

Research output: Contribution to journalArticle

Abstract

Early age at onset of breast cancer (eoBC) is suggestive of an increased genetic risk. Although genetic testing is offered to all eoBC-affected women, in isolated cases the detection rate of pathogenic variants is <10%. This study aimed at assessing the role of constitutive promoter methylation at BC-associated loci as an underlying predisposing event in women with eoBC and negative family history. Promoter methylation at 12 loci was assessed by the MassARRAY technology in blood from 154 BRCA1/2 negative patients with eoBC and negative family history, and 60 healthy controls. Hypermethylation was determined, within each promoter, by comparing the patient’s mean methylation value with thresholds based on one-sided 95% bootstrap confidence interval of the controls’ mean. Three patients had hypermethylated results, two at BRCA1 and one at RAD51C. Analyses on tumor tissue from the patient exceeding the highest threshold at BRCA1 revealed a mean methylation >60% and loss of heterozygosity at chromosome 17q. The patient hypermethylated at RAD51C showed low methylation in the tumor sample, ruling out a role for methylation-induced silencing in tumor development. In isolated eoBC patients, BRCA1 constitutive promoter methylation may be a predisposing event. Further studies are required to define the impact of methylation changes occurring at BC-predisposing genes and their role in tumorigenesis.

Original languageEnglish
Article number58
JournalCancers
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Methylation
Breast Neoplasms
Loss of Heterozygosity
Genetic Testing
Age of Onset
Neoplasms
Carcinogenesis
Chromosomes
Genes

Keywords

  • BRCA1
  • Breast cancer
  • Epigenetics
  • Promoter methylation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Constitutive BRCA1 promoter hypermethylation can be a predisposing event in isolated early-onset breast cancer. / Azzollini, Jacopo; Pesenti, Chiara; Pizzamiglio, Sara; Fontana, Laura; Guarino, Carmela; Peissel, Bernard; Plebani, Maddalena; Tabano, Silvia; Sirchia, Silvia Maria; Colapietro, Patrizia; Villa, Roberta; Paolini, Biagio; Verderio, Paolo; Miozzo, Monica; Manoukian, Siranoush.

In: Cancers, Vol. 11, No. 1, 58, 01.01.2019.

Research output: Contribution to journalArticle

Azzollini, Jacopo ; Pesenti, Chiara ; Pizzamiglio, Sara ; Fontana, Laura ; Guarino, Carmela ; Peissel, Bernard ; Plebani, Maddalena ; Tabano, Silvia ; Sirchia, Silvia Maria ; Colapietro, Patrizia ; Villa, Roberta ; Paolini, Biagio ; Verderio, Paolo ; Miozzo, Monica ; Manoukian, Siranoush. / Constitutive BRCA1 promoter hypermethylation can be a predisposing event in isolated early-onset breast cancer. In: Cancers. 2019 ; Vol. 11, No. 1.
@article{b3e26c242072415589fcae011013a420,
title = "Constitutive BRCA1 promoter hypermethylation can be a predisposing event in isolated early-onset breast cancer",
abstract = "Early age at onset of breast cancer (eoBC) is suggestive of an increased genetic risk. Although genetic testing is offered to all eoBC-affected women, in isolated cases the detection rate of pathogenic variants is <10{\%}. This study aimed at assessing the role of constitutive promoter methylation at BC-associated loci as an underlying predisposing event in women with eoBC and negative family history. Promoter methylation at 12 loci was assessed by the MassARRAY technology in blood from 154 BRCA1/2 negative patients with eoBC and negative family history, and 60 healthy controls. Hypermethylation was determined, within each promoter, by comparing the patient’s mean methylation value with thresholds based on one-sided 95{\%} bootstrap confidence interval of the controls’ mean. Three patients had hypermethylated results, two at BRCA1 and one at RAD51C. Analyses on tumor tissue from the patient exceeding the highest threshold at BRCA1 revealed a mean methylation >60{\%} and loss of heterozygosity at chromosome 17q. The patient hypermethylated at RAD51C showed low methylation in the tumor sample, ruling out a role for methylation-induced silencing in tumor development. In isolated eoBC patients, BRCA1 constitutive promoter methylation may be a predisposing event. Further studies are required to define the impact of methylation changes occurring at BC-predisposing genes and their role in tumorigenesis.",
keywords = "BRCA1, Breast cancer, Epigenetics, Promoter methylation",
author = "Jacopo Azzollini and Chiara Pesenti and Sara Pizzamiglio and Laura Fontana and Carmela Guarino and Bernard Peissel and Maddalena Plebani and Silvia Tabano and Sirchia, {Silvia Maria} and Patrizia Colapietro and Roberta Villa and Biagio Paolini and Paolo Verderio and Monica Miozzo and Siranoush Manoukian",
year = "2019",
month = "1",
day = "1",
doi = "10.3390/cancers11010058",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - Constitutive BRCA1 promoter hypermethylation can be a predisposing event in isolated early-onset breast cancer

AU - Azzollini, Jacopo

AU - Pesenti, Chiara

AU - Pizzamiglio, Sara

AU - Fontana, Laura

AU - Guarino, Carmela

AU - Peissel, Bernard

AU - Plebani, Maddalena

AU - Tabano, Silvia

AU - Sirchia, Silvia Maria

AU - Colapietro, Patrizia

AU - Villa, Roberta

AU - Paolini, Biagio

AU - Verderio, Paolo

AU - Miozzo, Monica

AU - Manoukian, Siranoush

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Early age at onset of breast cancer (eoBC) is suggestive of an increased genetic risk. Although genetic testing is offered to all eoBC-affected women, in isolated cases the detection rate of pathogenic variants is <10%. This study aimed at assessing the role of constitutive promoter methylation at BC-associated loci as an underlying predisposing event in women with eoBC and negative family history. Promoter methylation at 12 loci was assessed by the MassARRAY technology in blood from 154 BRCA1/2 negative patients with eoBC and negative family history, and 60 healthy controls. Hypermethylation was determined, within each promoter, by comparing the patient’s mean methylation value with thresholds based on one-sided 95% bootstrap confidence interval of the controls’ mean. Three patients had hypermethylated results, two at BRCA1 and one at RAD51C. Analyses on tumor tissue from the patient exceeding the highest threshold at BRCA1 revealed a mean methylation >60% and loss of heterozygosity at chromosome 17q. The patient hypermethylated at RAD51C showed low methylation in the tumor sample, ruling out a role for methylation-induced silencing in tumor development. In isolated eoBC patients, BRCA1 constitutive promoter methylation may be a predisposing event. Further studies are required to define the impact of methylation changes occurring at BC-predisposing genes and their role in tumorigenesis.

AB - Early age at onset of breast cancer (eoBC) is suggestive of an increased genetic risk. Although genetic testing is offered to all eoBC-affected women, in isolated cases the detection rate of pathogenic variants is <10%. This study aimed at assessing the role of constitutive promoter methylation at BC-associated loci as an underlying predisposing event in women with eoBC and negative family history. Promoter methylation at 12 loci was assessed by the MassARRAY technology in blood from 154 BRCA1/2 negative patients with eoBC and negative family history, and 60 healthy controls. Hypermethylation was determined, within each promoter, by comparing the patient’s mean methylation value with thresholds based on one-sided 95% bootstrap confidence interval of the controls’ mean. Three patients had hypermethylated results, two at BRCA1 and one at RAD51C. Analyses on tumor tissue from the patient exceeding the highest threshold at BRCA1 revealed a mean methylation >60% and loss of heterozygosity at chromosome 17q. The patient hypermethylated at RAD51C showed low methylation in the tumor sample, ruling out a role for methylation-induced silencing in tumor development. In isolated eoBC patients, BRCA1 constitutive promoter methylation may be a predisposing event. Further studies are required to define the impact of methylation changes occurring at BC-predisposing genes and their role in tumorigenesis.

KW - BRCA1

KW - Breast cancer

KW - Epigenetics

KW - Promoter methylation

UR - http://www.scopus.com/inward/record.url?scp=85061941993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061941993&partnerID=8YFLogxK

U2 - 10.3390/cancers11010058

DO - 10.3390/cancers11010058

M3 - Article

AN - SCOPUS:85061941993

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 1

M1 - 58

ER -